DOCSLIB.ORG

Minimising the Risk of Falls & Fall-Related Injuries

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Minimising the Risk of Falls & Fall-Related Injuries MinimisingMinimising thethe RiskRisk ofof FallsFalls & Fall-relatedFall-related InjuriesInjuries Guidelines for Acute, Sub-acute and Residential Care Settings Tools Supplement Published by the Metropolitan Health and Aged Care Services Division Disclaimer Victorian Government Department of Human Services This document should not be considered prescriptive. Health Melbourne Victoria care staff should work with patient/residents and their July 2004 families/carers to ensure that the most appropriate care and © Copyright State of Victoria, Department of Human Services, 2004 treatment is provided to the individual. Some flexibility will be required to adapt these Guidelines to specific settings, local This publication is copyright. No part may be reproduced by any process except in accordance with the circumstances and to individual patient/resident needs. provisions of the Copyright Act 1968. Every effort has been made to ensure that the information provided in this document is accurate and complete at the time Design by Watts Design. 3290 of development. However the Victorian Quality Council, the authors, or any person that has contributed to its development do not accept liability or responsibility for any errors or omissions that may be found, or any loss or damage incurred as a result of relying on the information in this document. Victorian Quality Council Secretariat Phone 1300 135 427 Email [email protected] website http://qualitycouncil.health.vic.gov.au VQC: MINIMISING THE RISK OF FALLS AND FALL-RELATED INJURIES: GUIDELINES FOR ACUTE, SUB-ACUTE AND RESIDENTIAL CARE SETTINGS: TOOLS SUPPLEMENT 1. INTRODUCTION 1 4. FALLS INCIDENT REPORT 30 How this Tools Supplement may be used 1 Falls Report – Goulburn Valley Health T.18 Types of sample tools included 1 How the sample tools were selected 1 5. POST-FALL PATHWAY 34 About the selected tools 2 Post Fall Team Management Protocol (The Alfred) T.19 Tips for selecting tools 2 Falls Pathway for a Patient who has Fallen (Western Health) T.20 2. FALLS RISK SCREENING (STEP 1) 6. PATIENT/RESIDENT INFORMATION RESOURCES 38 AND FALLS RISK ASSESSMENT (STEP 2) TOOLS 3 NARI/MECRS patient/resident brochure: A guide to reducing your risk Summary of Falls Risk Screening Tools (Step 1) & of falling while in hospital and Falls Risk Assessment Tools (Step 2) - Issues to note: 3 Queensland Health patient/resident Brochure: Falls Prevention Admission Risk Screening Tool – Melbourne Health T.01 Falls Risk Assessment Tool - Latrobe Regional Hospital T.02 7. MEDICATIONS ASSOCIATED WITH INCREASED Falls Risk Assessment: Residential Care - Melbourne Health and NARI T.03 FALLS RISK 40 Falls Screen - Latrobe Regional Hospital FARAM (Falls Assessment, Risk and Management) - Bayside Health T.05 8. VICTORIAN CORONER’S STANDARD FOR FRASS (Falls Risk Assessment Scoring System) - Bayside Health T.06 INVESTIGATION (OF FALL-RELATED DEATHS) 42 FRAT (Falls Risk Assessment Tool) – Peninsula Health T.07 Contents FRHOP (Falls Risk for Hospitalised Older People) 9. COGNITIVE IMPAIRMENT TESTS 46 – Melbourne Health and NARI T.08 Abbreviated Mental Test Score (AMTS) T21 PJC FRAT (Peter James Centre Falls Risk Assessment Tool) T.09 Mini-Mental State Examination (MMSE) T22 STRATIFY T.10 STRATIFY (modified Bendigo version) T.11 10.FALLS AND FALL-RELATED INJURY RISK The Northern Hospital modified STRATIFY T.12 MINIMISATION AUDIT 50 WHeFRA (Western Health Falls Risk Assessment) T.13 11.FALLS INCIDENT DATA MANAGEMENT 3. ENVIRONMENTAL AUDITS 26 FRAMEWORK (EXCEL FILE) 52 Peninsula Health Individual Environmental Checklist T.14 Queensland Health Individual Environmental Checklist T.15 Peninsula Health General Environmental Checklist T.16 Queensland Health General Environmental Checklist T.17 iv 01 Introduction How this Tools Supplement may a falls incident report Services and the Victorian Quality Council, and be used centres known to be involved in falls prevention post-fall pathways This Supplement contains a selection of falls project activity by the project team. patient/resident information resources and fall-related injury risk minimisation tools and The survey included questions about tools and resources for use in hospital and residential list of medications associated with resources in use in different areas of falls care settings. It should be used in conjunction increased falls risk minimisation activity, for example: with the Victorian Quality Councils “Minimising Falls and Fall-related injuries: Guidelines for Victorian Coroner’s Standard for falls risk screening tools Investigation (of falls related deaths) Acute, Sub-acute and Residential Care falls risk assessment tools settings” document and associated resources. Introduction cognitive impairment tests information brochures for patient/residents falls and fall-related injury risk minimisation and carers Types of sample tools included program audit, and The term ‘Tools’ refers to a range of support training programs, and falls incident data management framework documentation and resources that may be environmental audits. useful in the implementation of a program to (Excel file). The survey asked respondents: minimise the risk of falls and fall-related injuries Where possible, a range of sample tools have in hospitals or residential care settings. been selected for each type, to provide options to list the tool(s) they were using for use in different settings. The types of tools included are as follows: to identify whether it was an established falls risk screening tools tool(s) they had adopted, or was modified How the sample tools were selected or self-developed, and falls risk assessment tools A survey was distributed to Victorian hospitals whether they would recommend use of the 01 and residential care facilities, identified from lists environmental audits (both individual and tool(s) to other centres. general environment) generated by the Department of Human VQC: MINIMISING THE RISK OF FALLS AND FALL-RELATED INJURIES: GUIDELINES FOR ACUTE, SUB-ACUTE AND RESIDENTIAL CARE SETTINGS: TOOLS SUPPLEMENT A range of tools were contributed to the project and, based on the information provided, these tools were Tips for selecting tools reviewed by an Expert Panel for inclusion as samples in these Guidelines. The criteria used to conduct this review of the Tools are summarised as follows: Review examples of other tools used in a Criteria Description similar setting Face validity Does the tool appear to meet the intended purpose? Discuss the options with staff involved, Content/construct Any validation undertaken to support the utility/effectiveness of the tool taking into account their preferences about validity The factual accuracy (content validity) of the tool practical application The research evidence supporting the use of the type of tool Consider any research that has been done Utility The presentation style of the tool that supports the effectiveness of the The number of users/centres for a particular tool based on survey responses tool(s), particularly in a similar setting The number of users/centres for a particular tool based on survey responses Contact the developers of the tool(s) and that indicated they would recommend others to use the tool discuss any problems they have identified Other criteria Other features of the tool that might influence its rating with the use of their tool(s) Consider the usefulness of the tool(s) in While none of the tools reviewed met all of the criteria, recommended Tools have been selected based on supporting the implementation of strategies meeting the majority of the defined criteria. At the beginning of each section there is a table summarising the for falls and fall-related injury risk strengths and limitations of the tools. These tables may assist health care facilities to decide on the most minimisation in your setting. appropriate tool(s) for their setting. About the selected tools The tools provided are not intended to be representative of all available tools, nor are the samples intended to exemplify the ideal tools. They are intended to provide a starting point for organisations that wish to implement a program for minimising the risk of falls and fall-related injury or revise their current one. Given the substantial level of falls prevention activity currently happening in hospitals and residential care, it is envisaged that there will be a need to consider newly developed resources against similar criteria to determine their potential usefulness compared to those included in this document. The organisations involved in the development of the tools in this Supplement have given permission for the: inclusion of the tool in these Guidelines, and use of the tool by other organisations or centres, providing the source of the tool is acknowledged (information about the required acknowledgement is included on the introductory page for each tool). 02 02 Falls Risk Screening (Step 1) and Falls Risk Assessment (Step 2) Tools Refer to the Process Model in the Minimising Falls and Fall-related Injuries Guidelines and the supporting information for Steps 1 and 2 of the Process Model. Falls risk screening refers to a brief (often less than 5 item) check to identify patient/residents at risk of falling and who need to have a more detailed assessment of falls risk carried out. By contrast, falls risk assessment is a systematic, comprehensive process to identify an individual patient/resident’s risk factors for falling. Once identified, risk factors are used to develop Issues to note: the patient/resident’s falls and fall-related
Load more

Recommended publications
  • Comparison of the Antiischaemic and Antianginal Effects of Nicorandil and Amlodipine in Patients with Symptomatic Stable Angina Pectoris: the SWAN Study
    Journal of Clinical and Basic Cardiology An Independent International Scientific Journal Journal of Clinical and Basic Cardiology 1999; 2 (2), 213-217 Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study The SWAN Study Group Homepage: www.kup.at/jcbc Online Data Base Search for Authors and Keywords Indexed in Chemical Abstracts EMBASE/Excerpta Medica Krause & Pachernegg GmbH · VERLAG für MEDIZIN und WIRTSCHAFT · A-3003 Gablitz/Austria ORIGINAL PAPERS, CLINICAL The SWAN study J Clin Basic Cardiol 1999; 2: 213 Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study The SWAN Study Group1 This multicentre, double-blind, randomised study compared the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris. Nicorandil is a new coronary and balanced peripheral vasodilating agent that operates through two mechanisms of action: activation of ATP-dependent K-channels and stimulation of guanylate cyclase. A total of 121 patients with symptomatic stable angina pectoris were randomised to receive nicorandil 10 mg twice daily (bd) or amlodipine 5 mg once daily (od) for 8 weeks (optional dosage increase after 2-4 weeks to 20 mg bd and 10 mg od, respec- tively). Symptom-limited exercise tolerance tests were performed at baseline, and after 2 and 8 weeks treatment, respectively. In addition, the number of anginal attacks, nitroglycerin (NTG) usage, blood pressure (BP), heart rate (HR) and adverse events were recorded, and a subjective assessment of quality of life performed.
    [Show full text]
  • Management of Stable Angina in Adults
    Management of Stable Angina in Adults For new onset chest pain where angina is suspected patients should be referred to Rapid Access Chest Pain Service. ANTIANGINAL DRUG TREATMENT *see West Essex formulary for further choices Monotherapy: Beta blocker [Bisoprolol*] OR Calcium channel blocker (CCB) [Amlodipine*] N.B. In left-ventricular dysfunction (LVD), beta blocker therapy should be started at a low dose and titrated very slowly over a period of weeks or months. If beta-blockers or CCBs are not tolerated or both are contra- If a beta-blocker or Calcium Channel Blocker is indicated consider monotherapy with: contraindicated or not tolerated or symptoms are not a long-acting nitrate e.g. Isosorbide mononitrate MR controlled with a beta-blocker or CCB: Nicorandil Switch to the alternative drug Ivabradine (Restricted use – consultant initiation) or Ranolazine (Restricted use – consultant initiation) Do not combine ivabradine with a rate-limiting CCB, because it can Dual therapy: result in excessive bradycardia. Beta blocker AND Calcium Channel Blocker If symptoms are not controlled with a beta-blocker or If symptoms are not controlled with a beta-blocker or CCB alone DRUG THERAPY DRUG CCB, and neither are contraindicated: give a beta- and the other drug is contraindicated or not tolerated ADD: blocker AND CCB in combination. a long-acting nitrate or Do not combine a beta-blocker with a rate limiting Nicorandil CCB, as severe bradycardia and heart failure can Ivabradine (Restricted use – consultant initiation) or occur.3 Ranolazine (Restricted use – consultant initiation) NOTE Assess response to treatment 2-4 weeks after initiating or changing drug therapy; the drug should be titrated (according to symptom control) to the maximum tolerated dose.
    [Show full text]
  • Effects of Ketamine on Nicorandil Induced ATP-Sensitive Potassium Channel Activity in Cell Line Derived from Rat Aortic Smooth Muscle
    237 ORIGINAL Effects of ketamine on nicorandil induced ATP-sensitive potassium channel activity in cell line derived from rat aortic smooth muscle Takashi Kawano1, Katsuya Tanaka1, Yinhua1, Satoru Eguchi2, Hiroaki Kawano1, Akira Takahashi3, Yutaka Nakaya4, and Shuzo Oshita1 1Department of Anesthesiology, 2Department of Dental Anesthesiology, 3Department of Preventive Environment and Nutrition, and 4Department of Nutrition and Metabolism, Institute of Health Biosciences, the University of Tokushima Graduate School, Tokushima, Japan Abstract : Purpose : Nicorandil opens adenosine triphosphate-sensitive potassium (KATP) channels in the cardiovascular system and is being increasingly used for the treatment of angina pectoris. In the present study, we tested whether intravenous anesthetic agent ketamine affected nicorandil-induced native vascular KATP channel activation. Methods : We used excised inside-out patch clamp configurations to investigate the direct effects of ketamine racemate and S-(+)-ketamine on the activities of KATP channels in cultured rat aortic smooth muscle cells. Furthermore, we also investigated whether intracellular MgADP could modulate ketamine inhibition. Results : Nicorandil significantly activated KATP channel activity, whereas this channel activity was completely blocked by glibencla- mide, a specific KATP channel blocker. Ketamine racemate inhibited the nicorandil induced KATP channel activity (IC50 =34 1 !M, n=14), but S-(+)-ketamine was less potent than keta- mine racemate in blocking nicorandil induced KATP channel activities (IC50 =226 7 !M, n=10). Application of MgADP to the intracellular side of the channel was able to decrease the inhibitory potency of ketamine racemate on nicorandil induced KATP channel activities. Conclusions : Our results indicate that ketamine inhibits nicorandil induced KATP chan- nel activities in a dose dependent and stereoselective manner.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • Effects of Nicorandil on Inflammation, Apoptosis and Atherosclerotic
    biomedicines Article Effects of Nicorandil on Inflammation, Apoptosis and Atherosclerotic Plaque Progression Max Lenz 1,2 , Christoph Kaun 1, Konstantin A. Krychtiuk 1,2 , Patrick Haider 1, Mira Brekalo 1, Nadine Maier 1, Laura Goederle 3,4 , Christoph J. Binder 3,4, Kurt Huber 5 , Christian Hengstenberg 1 , Johann Wojta 1,2,6, Philipp J. Hohensinner 1,2,* and Walter S. Speidl 1 1 Department of Internal Medicine II—Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria; [email protected] (M.L.); [email protected] (C.K.); [email protected] (K.A.K.); [email protected] (P.H.); [email protected] (M.B.); [email protected] (N.M.); [email protected] (C.H.); [email protected] (J.W.); [email protected] (W.S.S.) 2 Ludwig Boltzmann Institute for Cardiovascular Research, 1090 Vienna, Austria 3 Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria; [email protected] (L.G.); [email protected] (C.J.B.) 4 Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria 5 3rd Medical Department for Cardiology and Emergency Medicine, Wilhelminenhospital and Sigmund Freud University, 1160 Vienna, Austria; [email protected] 6 Core Facility Imaging, Medical University of Vienna, 1090 Vienna, Austria * Correspondence: [email protected]; Tel.: +43-1-40400-73515 Abstract: Nicorandil, a balanced vasodilator, is used in the second-line therapy of angina pectoris. In this study, we aimed to illuminate the effects of nicorandil on inflammation, apoptosis, and Citation: Lenz, M.; Kaun, C.; atherosclerotic plaque progression.
    [Show full text]
  • The Combined Cardiac Effect of the Anabolic Steroid, Nandrolone And
    ù1. v -¿. rlc) 77.- *n*hi.rnool oowol,ù*o ffi"/fu -lo *rn*(o fii'o fio¿o¿¿, /v&"ùún lonno **al cooaiæe';¿vfl"- oã. Benjamin D. Phillis, B.Sc. (Hons) Phatmacology Depattment of Clinical & Experimental Pharmacology Ftome Rd. , Medical School Noth Adelaide Univetsity ADEIAIDE SA 5OOO û.)r.'-*hr/7enveltîù Foremost, I would like to thank my two supervisors for the direction that they have given this ptojecr. To Rod, for his unfailing troubleshooting abiJity and to Jenny fot her advice and ability to add scientific rigour' Many thanks to Michael Adams for his technical assistance and especially fot performing the surgery for the ischaemia-reperfusion projects and for his willingness to work late nights and public holidays. Lastly I would like to thank my v¡ife for her extreme patience during the tumult of the last 5 years. Her love, suppoït, patience and undetstanding have been invaluable in this endeavout. Beniamin D. Phillis Octobet,2005 ADE,I-AIDE ii T*(¿t of Ao,t",tù DECI.ARATION I ACKNOWLEDGEMENTS il TABLE OF CONTENTS UI ABBREVIATIONS x ABSTRACT )ilr CÉIAPTER t-l Inttoduction 1-1 1.1 Background 1,-1, 1.2What ate anabolic stetoids? 7-1 1,3 General pharmacology of Anabolic steroids t-2 '1,-2 1.3.1 Genomic effects of anabolic steroids 1.3.2 Non-genomic effects of anabolic steroids 1-3 1.4 Clinical use of AS 1.-4 1.5 Patterns of AS abuse 1.-4 1.5.1 Steroid abuse by athletes 1.-+ 1.5.2 Stetoid abuse by sedentary teenagers r-6 1.5.3 Prevalence of abuse 1-6 1.5.4 Abuse ptevalence in Australia 1.-9 1.6 Cardiotoxicity of anabolic steroids r-9 1.6.1 Reduced cotonary flow 1.-1.1, 1,.6.2 Dtect myocatdial eff ects 1-1 5 1.6.3 Hypertension 1-21 1.7 Difficulties associated with anabolic steroid research 1.-24 1-25 1.8 The polydrug abuse Phenomenon 1.9 The pharmacology of cocaine 1-26 1.10 Pteparations 1-28 1-29 1.11 Metabolism lll 1-30 1.
    [Show full text]
  • Nicorandil 10Mg Tablets
    Package leaflet: Information for the user Nicorandil 10mg Tablets Nicorandil 20mg Tablets Nicorandil Read all of this leaflet carefully before you may also develop on the skin, genital tract and start taking this medicine because it contains nasal passages or around a stoma (where there important information for you. is an artificial opening for waste removal such as • Keep this leaflet. You may need to read it again. a colostomy or ileostomy). These are more likely • If you have any further questions, ask your doctor to happen if you have a problem with your large or pharmacist. intestine (‘diverticular disease’). • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if Talk to your doctor before taking medicines for 9 their signs of illness are the same as yours. inflammation (corticosteroids) or non-steroidal • If you get any side effects, talk to your doctor or anti-inflammatory medicines including aspirin, pharmacist. This includes any possible side effects with Nicorandil Tablets. If taken together, you may Font: Font: Pil dimension :155x300 not listed in this leaflet. See section 4. be more likely to get ulcers or the other problems mentioned above. What is in this leaflet: These side effects can happen at the beginning of 1. What Nicorandil Tablets are and what they are treatment or later in treatment. Talk to your doctor used for straight away if you notice any of the signs above. 2. What you need to know before you take Nicorandil See section 4 for a full list of side effects.
    [Show full text]
  • Summary of Product Characteristics
    Irish Medicines Board Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Ikorel tablets 10 mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains Nicorandil 10 mg. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet Product imported from the UK: Round, off -white, circular tablets with faceted edges, scored on one side and with the marking 'IKI0' on the other side. The tablet can be divided into equal halves. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Ikorel is indicated for the prevention and management of angina pectoris. 4.2 Posology and method of administration The usual therapeutic range is 10mg to 20mg bid (twice a day). The usual starting dose is 10mg twice daily, in the morning and in the evening preferably, and should be titrated upwards in accordance with patients' needs, response and tolerance up to a maximum of 40mg bid, if necessary. A lower starting dose of 5mg bid may be used in patients particularly prone to headache. Elderly: There are no special dosage requirements for elderly patients, but as with all medicines the lowest effective dose should be used. Children: Not recommended. 4.3 Contraindications Nicorandil is contra -indicated in patients with: - Known idiosyncratic hypersensitivity to nicorandil or any of the excipients - cardiogenic shock - severe hypotension - left ventricular failure with low filling pressures - acute pulmonary oedema - myocardial infarction Due to the severe risk of hypotension, the concomitant use of nicorandil and phosphodiesterase 5 inhibitors (e.g. sildenafil, tadalfil, vardenafil) is contra indicated, since it can lead to a serious drop in blood pressure.
    [Show full text]
  • Pharmacological Management of Cardiac Syndrome Y: a Focused Review Ahmad Sharif-Yakan* and Christoph A
    : Ope gy n A lo c o c i e g s n s A Angiology: Open Access Yakan, Angiol Open Access 2015, 3:2 DOI: 10.4172/2329-9495.1000143 ISSN: 2329-9495 Review Open Access Pharmacological Management of Cardiac Syndrome Y: A Focused Review Ahmad Sharif-Yakan* and Christoph A. Nienaber Division of Cardiology, University Hospital Rostock, University of Rostock Faculty of Medicine, Rostock, Germany *Corresponding author: Ahmad Sharif-Yakan, Division of Cardiology, University Hospital Rostock, University of Rostock Faculty of Medicine, Ernst-Heydemann Str.6, 18059, Rostock, Germany, Tel: +493814947701; Fax: +493814947702; E-mail: [email protected] Recieved date: March 28, 2015; Accepted date: April 17, 2015; Published date: April 24, 2015 Copyright: © 2015 Yakan SA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract The Coronary slow flow phenomenon or cardiac syndrome Y is a relatively newly described microvascular coronary artery disorder that is still not fully understood. It is thought to be caused by increased flow resistance in the microvascular coronary artery beds. Patients affected by the CSY are typically young patients who suffer from myocardial ischemia at rest. Ischemia is often recurrent and as a result, patients suffer from a poor quality of life. The management of patients diagnosed with CSY is especially challenging, owing to its poorly understood pathophysiology, relatively recent recognition as a separate microvascular coronary artery disorder and most importantly the lack of large, homogenous, randomized controlled trials that compares the efficacy of various pharmacological agents.
    [Show full text]
  • Relaxation Responses of Ketamine and Propofol to Vasoactive Agents in Streptozotocin-Induced Diabetic Rats
    Niger. J. Physiol. Sci. 35 (June 2020) 33-39 www.njps.physiologicalsociety.com Research Article Relaxation Responses of Ketamine and Propofol to Vasoactive Agents in Streptozotocin-Induced Diabetic Rats Facey J., Young L. and Nwokocha C.R.* Department of Basic Medical Sciences (Physiology Section). The University of the West Indies, Mona, Kingston7, Jamaica Summary: Diabetes mellitus (DM) is a major risk factor for the development of endothelial dysfunction which affects the ability of blood vessels to regulate vascular tone. The study aimed to investigate the mechanisms of vasodilator action of the anaesthetic agents ketamine and propofol in diabetic rat aorta. 30 male Sprague-Dawley rats were randomly divided into two equal groups: (i) non-diabetic control (ii) Streptozotocin-induced diabetic group. DM was induced by a single intra-peritoneal injection of streptozotocin at 50 mg/kg body weight. Blood samples were taken from the tail vein after 24 hours and tested for glucose level using an automated glucose analyser. A blood glucose ≥10 mmol/L confirmed hyperglycaemia and the development of DM. Rats were sacrificed, and the aortae excised. The vascular responses of aortic rings from both groups to ketamine, propofol in the presence of vasoactive agents were studied using standard organ bath procedures. Ketamine and propofol reduced Phe-induced contraction similarly in the diabetic and control groups. Barium chloride, attenuated the relaxation response to propofol in diabetic aorta when compared to ketamine. 4-aminopyridine significantly attenuated the relaxation response to ketamine and propofol in diabetic aorta. Glibenclamide, significantly reduced ketamine-induced relaxation in diabetic aorta when compared to propofol.
    [Show full text]
  • In Vitro Inhibition of Breast Cancer Spheroid-Induced Lymphendothelial
    FULL PAPER British Journal of Cancer (2013) 108, 570–578 | doi: 10.1038/bjc.2012.580 Keywords: lymphendothelial intravasation; tumour spheroid; acetohexamide; nifedipin; isoxsuprine; proadifen In vitro inhibition of breast cancer spheroid-induced lymphendothelial defects resembling intravasation into the lymphatic vasculature by acetohexamide, isoxsuprine, nifedipin and proadifen N Kretschy1,8, M Teichmann1,8, S Kopf1, A G Atanasov2, P Saiko3, C Vonach1, K Viola1, B Giessrigl1, N Huttary1, I Raab1, S Krieger1,WJa¨ ger4, T Szekeres3, S M Nijman5, W Mikulits6, V M Dirsch2, H Dolznig7, M Grusch6 and G Krupitza*,1 1Institute of Clinical Pathology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria; 2Department of Pharmacognosy, University of Vienna, Althanstrasse 14, A-1090 Vienna, Austria; 3Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria; 4Department for Clinical Pharmacy and Diagnostics, Faculty of Life Sciences, University of Vienna, Althanstrasse 14, A-1090 Vienna, Austria; 5Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 14, AKH BT 25.3, A-1090 Vienna, Austria; 6Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria and 7Institute of Medical Genetics, Medical University of Vienna, Waehringer Strasse 10, A-1090 Vienna, Austria Background: As metastasis is the prime cause of death from malignancies, there is vibrant interest to discover options for the management of the different mechanistic steps of tumour spreading. Some approved pharmaceuticals exhibit activities against diseases they have not been developed for. In order to discover such activities that might attenuate lymph node metastasis, we investigated 225 drugs, which are approved by the US Food and Drug Administration.
    [Show full text]
  • Once-Daily Sustained-Release Matrix Tablets of Nicorandil: Formulation and in Vitro Evaluation Submitted: September 4, 2003; Accepted: October 20, 2003 K
    AAPS PharmSciTech 2003; 4 (4) Article 61 (http://www.aapspharmscitech.org). Once-Daily Sustained-Release Matrix Tablets of Nicorandil: Formulation and In Vitro Evaluation Submitted: September 4, 2003; Accepted: October 20, 2003 K. Raghuram Reddy,1 Srinivas Mutalik,1 and Srinivas Reddy1 1College of Pharmaceutical Sciences, Manipal-576119, Karnataka, India ABSTRACT KEYWORDS: nicorandil, hydroxypropyl methylcellulose, The objective of the present study was to develop once-daily ethylcellulose, sustained release, matrix tablets sustained-release matrix tablets of nicorandil, a novel potas- sium channel opener used in cardiovascular diseases. The INTRODUCTION tablets were prepared by the wet granulation method. Etha- nolic solutions of ethylcellulose (EC), Eudragit RL-100, Hypertension and angina pectoris, the most common car- Eudragit RS-100, and polyvinylpyrrolidone were used as diovascular diseases, require constant monitoring. Potas- granulating agents along with hydrophilic matrix materials sium channel openers are presently considered an important like hydroxypropyl methylcellulose (HPMC), sodium car- class of drugs for hypertension and angina pectoris. The first boxymethylcellulose, and sodium alginate. The granules therapeutic drug shown to possess an ability to hyperpolar- were evaluated for angle of repose, bulk density, compressi- ize smooth muscle cell membranes is nicorandil, a potent bility index, total porosity, and drug content. The tablets coronary vasodilator.1 Although nicorandil is one of the were subjected to thickness, diameter, weight variation test, emerging molecules in the case of hypertension and angina, drug content, hardness, friability, and in vitro release stud- successful treatment means maintenance of blood pressure ies. The granules showed satisfactory flow properties, com- at a normal physiological level, for which a constant and pressibility, and drug content.
    [Show full text]